Platelets and platelet-derived vesicles as an innovative cellular and subcellular platform for managing multiple...

Area of Science:

• Neuroimmunology
• Drug Delivery Systems
• Biomaterials

Background:

• Multiple sclerosis (MS) is a progressive inflammatory autoimmune disease affecting young individuals.
• Current MS treatments have limitations, including chronic, non-targeted effects and low central nervous system (CNS) drug concentrations due to the blood-brain barrier (BBB).
• Innovative, targeted drug delivery methods are crucial for effective MS therapy.

Purpose of the Study:

• To explore the potential of activated platelets as a drug delivery system for targeting the CNS in MS.
• To review the role of platelets in modulating inflammation within the CNS and peripheral areas in MS.

Main Methods:

• Review of existing literature on platelet function in inflammation and MS.
• Analysis of platelet's role in cell recruitment and inflammatory modulation.
• Evaluation of platelet-based systems for drug targeting to the CNS.

Main Results:

• Activated platelets play a significant role in inflammatory conditions by recruiting cells to injured sites and limiting inflammation.
• Platelets demonstrate a crucial role in mitigating inflammation progression in both peripheral and CNS areas during different stages of MS.
• Platelets possess inherent properties suitable for targeted drug delivery.

Conclusions:

• Platelet-based drug delivery systems are promising biomimetic candidates for MS therapy.
• These systems can facilitate targeted drug delivery to the CNS.
• Platelet-based approaches can effectively limit inflammation in both peripheral and central areas for MS treatment.